AI is surfacing within regulatory and CMC workflows at a vigorous pace. Unfortunately, in small and midsize biotechs, it's happening faster than governance can keep up.
- CDMO Selection: Start With The Relationship, Not The RFP
- Why FAT Should Confirm Alignment, Not Reveal Its Absence
- What Reliance, Annex 1, And AI Mean For The Future Of GMP
- Applying Contamination Control By Design: A Practical Guide For CDMOs
- What To Do About Process Drift In Your Biosimilar's Reference Product
- Field Notes: Freeing Process Data For Automation At Kivi Bio AI Summit
- Rethinking CQV In A Digital, Agile Manufacturing Landscape
GUEST COLUMNISTS
-
CDMO Selection: Start With The Relationship, Not The RFP
Friction often comes from unspoken expectations. Before production begins, treat the combined sponsor-CDMO group as one extended team and intentionally make “how we work together” visible.
-
Why FAT Should Confirm Alignment, Not Reveal Its Absence
In many aseptic fill/finish projects, the factory acceptance test (FAT) has become the first true integration test of the entire project. That is a problem. Here's how to flip that mindset.
-
What Reliance, Annex 1, And AI Mean For The Future Of GMP
EMA’s Brendan Cuddy explains how regulators are adapting oversight to global supply chains, new technologies, and growing operational complexity.
-
Applying Contamination Control By Design: A Practical Guide For CDMOs
This article addresses the three contamination control challenges that are specific to the CDMO environment, provides five practical steps any organization can act on now, and more.
-
What To Do About Process Drift In Your Biosimilar's Reference Product
Biosimilar development often reveals quality drifts in certain lots of the reference biologic. In most cases, quality changes are noncritical, but some drifts can impact CQAs.
-
Field Notes: Freeing Process Data For Automation At Kivi Bio AI Summit
The missing link between data generation and unleashing it to power automation often lies in well-governed cloud infrastructure.
-
Rethinking CQV In A Digital, Agile Manufacturing Landscape
While commissioning, qualification, and validation (CQV) remains foundational, the way it is planned and executed must evolve to keep pace with modern manufacturing realities.
BIOSIMILAR WHITE PAPERS
-
Revolutionizing Drug Discovery From "Undruggables" To AI
Explore four current trends in drug discovery, how each trend addresses some of the most crucial challenges in drug discovery, and the obstacles to their widespread adoption.
-
2024 Global Biopharma Sustainability Review9/3/2024
What steps is the biopharma industry taking to enhance sustainability? What challenges does biopharma encounter? And how can the entire industry draw lessons from the companies setting the standard?
-
Business Continuity Management: The Benzonase® Endonuclease Success Story8/21/2024
Business continuity management is a key success contributor to the pharma industry. Explore best practices for a robust supply chain and how they can translate into success stories.
-
Optimizing Safety Measures For rAAV Therapies10/11/2024
Explore common process-related impurities found in recombinant Adeno-Associated Virus (rAAV) vectors and the analytical testing methods used for these residuals.
-
Why Choose Robotic Processing For Small Batch Aseptic Filling1/9/2026
Reducing human intervention in aseptic filling is critical for safety and cost efficiency. Learn why automation is essential for small-batch applications and how it’s transforming sterile drug manufacturing.
-
A Comprehensive Solution For Adventitious Agent Testing2/13/2026
Modern sequencing methods offer sensitive detection of adventitious and species‑specific viruses. Learn how targeted and non‑targeted NGS approaches improve confidence in cell bank characterization.
BIOSIMILAR APP NOTES & CASE STUDIES
- Benchmarking Filtration Performance Of TFF Cassettes
- Balancing Protein A Resin Cost, Performance, And Productivity
- Enabling Accelerated Raman Model Calibration For Real-Time Monitoring
- Scale-Up Of AAV Production In Fixed-Bed Bioreactors
- Virus Retention Performance Under Diverse Processing Conditions
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- Chime Biologics And Daewoong Pharmaceutical Enter Strategic Partnership To Advance Dupilumab Biosimilar Development And Commercialization In Global Markets
- USP Publishes Product-Specific Emerging Biologics Standards For Public Comment
- Henlius' Pertuzumab Approved In China, Solidifying Breast Cancer Strategy As The First China-US-EU Approved Chinese Trastuzumab-Pertuzumab Combination
- Boan Biotech Submits A Biologics License Application For Two Denosumab Biosimilars In The U.S.
- Samsung Bioepis Launches OPUVIZ (Aflibercept) 40 mg/mL Vial Across Europe, To Treat Ophthalmic Conditions
- Globalisation 2.0 | First Patient Dosed In China For International Multi-Centre Phase 1 Clinical Trial Of Henlius' Subcutaneous Daratumumab Biosimilar HLX15-SC
- Polpharma Biologics And Tuteur Sign Licensing Agreement For A Biosimilar For Autoimmune Diseases
- Mabwell Announces NMPA Approval Of Supplemental Application For Additional Indications Of MAIWEIJIAN (Denosumab Injection)
NEWSLETTER ARCHIVE
- 05.21.26 -- Minimizing Regulatory Risk For Biologics Manufacturing Changes
- 05.14.26 -- Do Changes Signal The End Of Biosimilar Regulatory Redundancy?
- 05.07.26 -- The Business Case For Continuous Manufacturing In Biologics
- 04.30.26 -- Quantifying Single-Use Waste Produced During mAb Manufacture
- 04.16.26 -- Innovation That's Redefining Aseptic Filling